NEW YORK (GenomeWeb News) – Saladax Biomedical today announced Ilex Medical will exclusively distribute three of its tests in Israel.

Under the agreement, Ilex will distribute My5-FU, MyPaclitaxel, and MyDocetaxel diagnostic reagent kits, which are designed to measure the level of the chemotherapy drugs in blood "to overcome the limitations associated with dosing based on body surface area," or BSA, Saladax said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.